These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 27725637)

  • 1. Prostate cancer: Targeting apoptosis resistance in CRPC.
    Thoma C
    Nat Rev Urol; 2016 Nov; 13(11):631. PubMed ID: 27725637
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance.
    Fenner A
    Nat Rev Urol; 2016 Dec; 13(12):695. PubMed ID: 27779227
    [No Abstract]   [Full Text] [Related]  

  • 8. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Kashiwagi E; Masubuchi D; Eto M; Uchiumi T; Naito S
    Oncogene; 2010 Jan; 29(2):237-50. PubMed ID: 19802001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 11. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
    Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
    Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
    Pandit-Taskar N; Veach DR; Fox JJ; Scher HI; Morris MJ; Larson SM
    J Nucl Med; 2016 Oct; 57(Suppl 3):73S-78S. PubMed ID: 27694177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
    Jeong JH; Park SJ; Dickinson SI; Luo JL
    Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms for castration-resistance of prostate carcinoma].
    Chen F; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1217-1221. PubMed ID: 29093256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.